Actively Recruiting
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
Led by BeOne Medicines · Updated on 2026-05-11
84
Participants Needed
4
Research Sites
159 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BG-C0979 monotherapy or in combination with tislelizumab in participants with selected advanced solid tumors. The study will consist of Phase 1a (Dose Escalation and Safety Expansion) and Phase 1b (Dose Expansion).
CONDITIONS
Official Title
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults with histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors
- For Phase 1a and Phase 1b Part A: Participants previously treated with standard systemic therapy or for whom such treatment is not available, not tolerated, or deemed inappropriate
- For Phase 1b Part B: Participants with metastatic or unresectable advanced solid tumors who have not received prior systemic treatment for advanced or metastatic disease
- Must have at least one measurable lesion by RECIST v1.1
- Must have a stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Must have adequate organ function
You will not qualify if you...
- Prior treatment with any ADAM9-targeted antibody-drug conjugates or ADCs containing TOPO1 inhibitor as payload
- Active leptomeningeal disease or uncontrolled, untreated brain metastasis
- Other protocol defined inclusion/exclusion criteria may apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Next Oncology San Antonio
San Antonio, Texas, United States, 78229
Actively Recruiting
2
Northern Beaches Hospital
Frenchs Forest, New South Wales, Australia, NSW 2086
Actively Recruiting
3
Icon Cancer Centre South Brisbane
South Brisbane, Queensland, Australia, QLD 4101
Actively Recruiting
4
Second Affiliated Hospital of Army Medical University (Xinqiao Hospital)
Chongqing, Chongqing Municipality, China, 400037
Actively Recruiting
Research Team
S
Study Director
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here